tirzepatide and fasting Efficacy Safety of in Type 2 Diabetes and Obesity Management After starting Mounjaro (Tirzepatide), many

10.1055/s-0035-1569330 35 DarabianS.HormuzM.LatifM

Its Phase 3 TRIUMPH-4 results, released in December 2025, were staggering: 28.7% average body weight loss at 12mg the highest figure ever recorded in a Phase 3 obesity trial

J Biol Chem 193:265275 Marchetti DP, Steffens L, Jacques CE, Guerreiro GB, Mescka CP, Deon M, de Coelho DM, Moura DJ, Viario AG, Poletto F, Coitinho AS, Jardim LB, Vargas CR (2018) Oxidative imbalance, Nitrative stress, and inflammation in C6 glial cells exposed to Hexacosanoic acid: protective effect of N-acetyl-lcysteine, Trolox, and Rosuvastatin

Because orlistat is currently the only anti-obesity drug approved for long-term use, the development of new anti-obesity drugs is therefore urgently needed

Clinical trials show up to 12.4% weight loss over 72 weeks in non-diabetic patients, positioning it as a potential blockbuster